What is the official website of Merck Group ?

The official website of Merck Group is http://www.merckgroup.com.

What is Merck Group's cybersecurity risk score?

Merck Group has an AI-generated cybersecurity risk score of 674 out of 1000, indicating a Weak security posture according to Rankiteo's assessment.

How many security incidents has Merck Group experienced?

According to Rankiteo, Merck Group currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Merck Group been affected by any supply chain cyber incidents ?

According to Rankiteo, Merck Group has been affected by a supply chain cyber incident involving Snowflake, with the incident ID MEREQUUNIMAEMGMGOOTOYSNOALLORARIPTIC1775528897.

Does Merck Group have SOC 2 Type 1 certification ?

According to Rankiteo, Merck Group is not certified under SOC 2 Type 1.

Does Merck Group have SOC 2 Type 2 certification ?

According to Rankiteo, Merck Group does not hold a SOC 2 Type 2 certification.

Does Merck Group comply with GDPR ?

According to Rankiteo, Merck Group is not listed as GDPR compliant.

Does Merck Group have PCI DSS certification ?

According to Rankiteo, Merck Group does not currently maintain PCI DSS compliance.

Does Merck Group comply with HIPAA ?

According to Rankiteo, Merck Group is not compliant with HIPAA regulations.

Does Merck Group have ISO 27001 certification ?

According to Rankiteo,Merck Group is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Merck Group operate in ?

Merck Group operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Merck Group have ?

Merck Group employs approximately 32,268 people worldwide.

Does Merck Group own any subsidiaries ?

Merck Group presently has no subsidiaries across any sectors.

How many LinkedIn followers does Merck Group have ?

Merck Group's official LinkedIn profile has approximately 1,643,572 followers.

What is the NAICS classification code for Merck Group ?

Merck Group is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Merck Group have a Crunchbase profile ?

No, Merck Group does not have a profile on Crunchbase.

Does Merck Group have a LinkedIn profile ?

Yes, Merck Group maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/merck-group.

How many cybersecurity incidents has Merck Group experienced ?

As of July 4, 2026, Rankiteo reports that Merck Group has experienced 1 cybersecurity incidents.

How many peer or competitor companies does Merck Group have ?

Merck Group has an estimated 5,700 peer or competitor companies worldwide.

What types of cybersecurity incidents has Merck Group faced ?

Incident Types: The types of cybersecurity incidents that have occurred include Ransomware.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Merck Group

Boost Score +25 with badge (5 left)

674

/1000

Weak

699

/1000

Weak

Merck Group Vendor Cyber Rating & Cyber Score

merckgroup.com

Add Your Compliance Badge

This channel is not intended for U.S. and Canadian visitors. Merck operates in the U.S. and Canada as EMD Serono in Healthcare, MilliporeSigma in Life Science and EMD Electronics in Electronics. An unaffiliated and unrelated company, Merck & Co., Inc., Kenilworth, NJ, US holds the rights in the trademark MERCK in the U.S. and Canada. _______________________________ We are Merck, a leading global science and technology company headquartered in Germany. We are curious explorers, courageous pioneers, and ingenious inventors. Our colleagues across the globe love innovating with science and technology to enrich people’s lives with our solutions in Life Science, Healthcare, and Electronics. Together, we dream big and are passionate about

Merck Group A.I CyberSecurity Scoring

Scoring History

Merck Group

Merck Group CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

Merck Group

Ransomware

100

12/2025

Snowflake

MEREQUUNIMAEMGM...

Loading…

A.I.

Merck Group Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Merck Group

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Merck Group in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Merck Group in 2026.

Incident Types Merck Group vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Merck Group in 2026.

Incident History - Merck Group (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Merck Group Subsidiaries

Merck Group

Pharmaceutical Manufacturing

Website: http://www.merckgroup.com

Company Size: 10,000+ employees

Merck Life ScienceBiotechnology Research

Merck HealthcarePharmaceutical Manufacturing

Merck ElectronicsChemical Manufacturing

Loading…

Merck Group Similar Companies

Grifols

cb linktr.ee

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people all over the world. A leader in essential plasma-derived medicines and transfusion medicine, we develop, produce and provide innovative healthcare services and solutions in more than 110 countries. Patient needs and our ever-growing knowledge of many chronic, rare and prevalent diseases, sometimes life-threatening, drive our innovation in plasma-based therapies and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious diseases. With a workforce of over 23,000 employees in more than 30 countries and regions, we are committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership in the industry. Our work has a positive social and economic impact in the countries where we operate, creating jobs and generating wealth. People are at the heart of what we do, and we strive to create an inclusive, diverse, fair and equal society. Maintaining and promoting a workforce that reflects this reality leads to enhanced professional relationships and helps us to give our best to patients, donors and customers. In 2024, Grifols was named one of TIME’s ‘World’s Best Companies’ for the second year in a row, reaffirming our commitment to excellence. We were also recognized by Forbes as one of the "Best Employers for Women 2023," reflecting our dedication to fostering an inclusive and supportive workplace for all. To maintain a positive community and overall respectful communication, please keep our community guidelines in mind.

Alkem Laboratories Ltd.

alkemlabs.com

A single idea, which sprouts from a human mind, contains the potential to create marvels that can influence generations. It can redefine rules, it can transform the world. Back in the year 1973, a team of individuals came with such an idea – The idea called Alkem. It was highly potent and resilient, like a spark that could ignite a thousand more ideas. And it did! Looking back at our 4 decade, illustrious journey, that one small idea has Not only triggered us to become one of India’s largest generic and specialty pharmaceutical company but also, create a foothold in over 50 countries 32% of our revenue is generated via offshore sales. As well as we have consistently been ranked amongst the top ten pharmaceutical companies in India. Our portfolio includes illustrious brands like Clavam, Pan, Pan-D and Taxim-O, which feature amongst top 50 pharmaceutical brands in India. For over a decade, our dominance in anti-infective segment has remained unchallenged. We have 21 manufacturing facilities at multiple locations in India and the United States of America. Our upper-crest facilities are inspected and audited as per cGMP guidelines as laid down by leading regulatory authorities such as USFDA, MHRA - UK, SAHPRA-South Africa, TGA - Australia, ANVISA - Brazil, WHO - Geneva, TPD - Health Canada, PPB - Kenya, NDA - Uganda, MOH - Sudan, INVIMA - Colombia, TFDA - Tanzania, Zimbabwe, BfArM-Germany & Other Africa, Asian & CIS Countries. Another feather in our cap was added on December 23rd, 2015, when, Alkem completed it's Initial Public Offering (IPO) and was listed on the Bombay Stock Exchange Limited and the National Stock Exchange of India Limited. Although passion is the fuel that keeps ideas alive, innovation is the catalyst that gives it flight! With over 500 scientists working in 5 global R&D centers, we are empowering innovations that align with our philosophy of ‘Extended Lifecare Beyond Boundaries’.

Cipla

cipla.com

Cipla is a leading global pharmaceutical company trusted by healthcare professionals and patients across the world since 1935. A compassionate approach to healthcare that goes beyond the pursuit of profit and growth has been the force impelling Cipla’s history over the years. Our credo and our purpose of ‘Caring for Life' continues to guide our actions towards our people and the planet for creating a sustainable future. Cipla today has presence in 80+ countries, providing over 1,500 products across various therapeutic categories in 50+ dosage forms. Keeping with our legacy of care, we constantly strive to ensure access to high-quality medicines that make a difference in the lives of patients. Our paradigm-changing offer of a triple anti-retroviral (ARV) therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 was pivotal in bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. An unmatched presence across the care continuum (awareness, prevention, diagnosis, treatment and adherence) and the widest range of drug-device combinations has established Cipla’s respiratory leadership in India and other key emerging markets. Armed with this legacy and a deep understanding of the lungs, we have articulated our aspiration to become a global lung leader and help millions breathe free.

Catalent

catalent.com

Championing the missions that matter™. Catalent, Inc. is a leading global contract development and manufacturing organization (CDMO) and trusted partner to pharma, biotech, and consumer health companies worldwide. We put patients first in everything we do, helping people live better and healthier lives through every product we help develop, manufacture and deliver. With over 1,000 active development programs at any given time, we launch over 100 new products and line extensions annually. Catalent has supported half of all FDA approvals over the past decade, and our teams working at over 40 global sites help us produce over 60 billion doses every year. Our strength lies in our people: teams across our more than 40 sites and thousands of passionate scientists and technicians who bring expertise in development sciences, delivery technologies, and multi-modality manufacturing. What unites us is our commitment to championing our partners’ missions as our own, anticipating customer needs, solving complex challenges and ultimately making a difference in the lives of patients across the globe. At Catalent, you will be able to directly have an impact, solving problems and ensuring excellence for our customers. Our focus on delivering meaningful outcomes alongside our customers means your work directly impacts millions of people around the world. Join us in championing the missions that matter. Catalent is headquartered in Tampa, Florida, with over 40 global sites. Visit www.catalent.com to learn more.

Torrent Pharmaceuticals Ltd

cb torrentpharma.com

Torrent Pharma, with annual revenues of more than Rs 10,700 crores, is the flagship Company of the Torrent Group, with group revenues of Rs 41,000 crores. It is ranked 5th in the Indian Pharma Market and is among the Top 5 in the therapeutic segments of Cardiovascular (CV), Central Nervous System (CNS), Gastro-intestinal (GI), Vitamins Minerals Nutritionals (VMN) and Cosmo-Dermatology. The Company also has significant presence in diabetology, pain management, gynaecology, oncology and anti-infective segments. Torrent has 8 manufacturing facilities , of which 5 are USFDA approved. With R&D as the backbone for its growth in domestic & overseas market, it has invested significantly in R&D capabilities with state-of-the-art R&D infrastructure employing around 800 scientists. The acquisition of Elder Pharma's Indian branded business in 2013, Dermaceuticals business of Zyg Pharma in 2015, API plant of Glochem Industries in 2016, Women healthcare brands from Novartis and Unichem's Indian branded business along with its Sikkim Plant in 2017 strengthened Torrent Pharma's position in the Indian Pharma market. Torrent Pharma started international acquisitions in 2005 with entry into the German market. Today, the Company has presence in more than 50 countries and is ranked No. 1 among the Indian pharma Companies in Brazil and Germany. Torrent Pharma is committed towards “not just healthcare but lifecare.”

Dr. Reddy's Laboratories

drreddys.com

Established in 1984, we are a global pharmaceutical company headquartered in Hyderabad, India. Driven by our purpose of ‘Good Health Can’t Wait’, we work to provide access to affordable and innovative medicines. We offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major markets include USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in future growth drivers such as access to novel molecules, digital therapeutics and consumer healthcare. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com. Caution Notice: Dr. Reddy's has been made aware of candidates receiving fraudulent job opportunities from unauthorised recruiting agencies or people impersonating Dr. Reddy's leaders. These fraudulent jobs may be advertised on employment sites or mimic our careers site and company email addresses. Please know that Dr. Reddy's Laboratories has no affiliation or connection to these situations. Dr. Reddy's (and its associated/group companies) follows a formal recruitment process through its own HR department. Please report immediately in case you suspect a fraudulent job. You may raise your concern by: Accessing https://drreddys.ethicspoint.com. Calling on the hotline number. List of hotline numbers are available in https://drreddys.ethicspoint.com. The hotline is available 24x7 in multiple languages. Writing to [email protected] or [email protected]. For our community guidelines on LinkedIn, please visit: https://shorturl.at/LTvNZ

Zoetis

zoetis.com

The world’s leading animal health company. We’ve been innovating ways to predict, prevent, detect, and treat animal illness for over 70 years, and we continue to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock farmers. Our leading portfolio and pipeline makes a difference in over 100 countries. Community Guidelines: This page is intended to share how Zoetis is advancing care for animals. We aspire to create a supportive community, but there are guidelines to which posts and comments on this page must adhere. If your post references a side effect related to any Zoetis product, we may contact you for more information. To monitor the safety of Zoetis products, we advise you to call our Veterinary Medical Information and Product Support Team at 1-888-963-8471; Support Team is available Mon-Fri 9am to 6:30pm ET. We reserve the right to remove any post/comment that violates LinkedIn Guidelines. As a last resort, we reserve the right to block users that demonstrate a repeated pattern of violating LinkedIn’s spirit of constructive, professional discourse. We respectfully request that you refrain from posting comments including: Unsolicited and/or unverified medical advice Vulgarity and/or profanity Discriminatory and/or derogatory comments, hate speech Politics and religion Personal attacks and/or threats Promotion of illegal activity Copyright/trademark infringements Topics that may be considered spam/advertising Our regular business hours are Mon-Fri 9am to 5pm ET. Zoetis does not endorse and is not responsible for information and opinions shared by community members. The information shared is provided for educational purposes only and is not intended to replace discussions with an animal healthcare professional. Testimonials represent individual experience only and the experiences and opinions of community members may be unique to the speaker. Terms of Use: https://www.zoetis.com/terms-of-use

Zydus Group

zyduslife.com

The Zydus Group with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global life-sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 27000 people worldwide and is driven by its mission to unlock new possibilities in life-sciences through quality healthcare solutions that impact lives. The group aspires to transform lives through pathbreaking discoveries.

Lonza

lonza.com

Lonza is a pioneer and world leader in the CDMO industry, setting the pace with cutting-edge science, smart technology, and lean manufacturing. United by a common purpose, we turn our customers’ breakthrough innovations into viable therapies and manufacture the medicines of tomorrow. Founded in Switzerland in 1897, our company is the first and original CDMO, and today we are more dynamic, agile and forward-focused than ever before. As one of the largest Western CDMOs, we bring together a global team of around 18,500 colleagues across five continents to deliver comprehensive, integrated solutions for our customers' complex needs. For our customers and their patients, we bring quality, safety and reliability to bring life-enhancing and life-saving treatments to market at speed and at scale. For our colleagues, we strive to create a sense of belonging and inclusion where every person can thrive and bring their best.

Loading…

NEWS

Merck Group CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

March 19, 2026 07:00 AM

How The Investment Story For Merck KGaA (XTRA:MRK) Is Quietly Shifting On Cautious Targets

A small reset in fair value to €143.20, together with individual analyst targets moving to €135 from €150 and to €130 from €125,...

Read Article

March 06, 2026 08:00 AM

Germany’s Merck KGaA Expects Currency Headwinds to Weigh on Earnings

It projected lower adjusted earnings and flat sales at best for 2026.

Read Article

March 05, 2026 08:00 AM

Merck KGaA Q4 Earnings Call Highlights

Merck KGaA (ETR:MRK) executives told investors the company delivered “solid” organic growth in 2025 despite a challenging macroeconomic and...

Read Article

March 05, 2026 08:00 AM

Merck KGaA sees earnings drop on currency effects, MS drug

Germany's Merck KGaA projected 2026 adjusted operating profit to slip by as much as 9.8%, hurt by negative currency effects and the loss of...

Read Article

March 03, 2026 08:00 AM

List of Fortune 500 Chief Information Security Officers

Every one of our nation's biggest businesses has a cybersecurity leader. Scroll down the list to see who's who.

Read Article

January 14, 2026 08:00 AM

Is Merck KGaA (XTRA:MRK) Share Price Misaligned With Cash Flow And Earnings Valuation Estimates

If you are wondering whether Merck KGaA is offering fair value at its current share price, this article will walk you through what the...

Read Article

November 20, 2025 08:00 AM

Merck KGaA to draw on Valo's drug discovery AI in potential $3 billion deal

Germany's Merck KGaA on Thursday agreed to use Boston-based Valo Health's drug research services in a collaboration focused on Parkinson's...

Read Article

November 13, 2025 08:00 AM

Germany’s Merck KGaA Shares Rise After Semiconductor, Pharma Demand Boost Results

The company's life-science segment—its largest by sales—benefited from strong demand from the pharma industry, continuing a recovery...

Read Article

November 12, 2025 08:00 AM

Merck KGaA's Q3 profit rises, beats market view

Merck KGaA on Thursday reported a slight gain in third-quarter operating earnings that beat market expectations, benefiting from legislative...

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-58523

SUMMARY

Improper access control in Microsoft Edge for Android allows an unauthorized attacker to bypass a security feature over a network.

Published

Date2026-07-03

Updated

Date2026-07-03

RISK INFORMATION (Score: 6.5)

cvss3

Base Score: 6.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:U/C:H/I:N/A:N

Impact Score

3.6

Exploitability

2.8

REFERENCES

https://msrc.microsoft.com/update-guide/vulnerability/CVE-2026-58523

CVE-2026-14617

SUMMARY

A security vulnerability has been detected in NousResearch hermes-agent up to 2026.4.30. Affected is the function GatewayStreamConsumer._filter_and_accumulate of the file gateway/stream_consumer.py of the component Streaming Reasoning Tag Filter. The manipulation leads to improper handling of case sensitivity. The attack may be initiated remotely. The attack's complexity is rated as high. The exploitability is told to be difficult. The exploit has been disclosed publicly and may be used. The project decided to not implement a dedicated fix: "[T]he analysis and the fix are both sound. It just lands below the bar for the maintenance cost of a duplicated scrub path."

Published

Date2026-07-03

Updated

Date2026-07-03

RISK INFORMATION (Score: 3.1)

cvss2

Base Score: 2.1

Complexity: HIGH

AV:N/AC:H/Au:S/C:P/I:N/A:N

cvss3

Base Score: 3.1

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:L/UI:N/S:U/C:L/I:N/A:N

cvss4

Base Score: 1.3

Complexity: HIGH

CVSS:4.0/AV:N/AC:H/AT:N/PR:L/UI:N/VC:L/VI:N/VA:N/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

1.4

Exploitability

1.6

REFERENCES

CVE-2026-58597

SUMMARY

Insufficient ui warning of dangerous operations in Microsoft Edge (Chromium-based) allows an unauthorized attacker to perform spoofing over a network.

Published

Date2026-07-03

Updated

Date2026-07-03

RISK INFORMATION (Score: 4.3)

cvss3

Base Score: 4.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:U/C:L/I:N/A:N

Impact Score

1.4

Exploitability

2.8

REFERENCES

https://msrc.microsoft.com/update-guide/vulnerability/CVE-2026-58597

CVE-2026-58524

SUMMARY

Improper neutralization of input during web page generation ('cross-site scripting') in Microsoft Edge (Chromium-based) allows an unauthorized attacker to perform spoofing over a network.

Published

Date2026-07-03

Updated

Date2026-07-03

RISK INFORMATION (Score: 5.4)

cvss3

Base Score: 5.4

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:U/C:L/I:L/A:N

Impact Score

2.5

Exploitability

2.8

REFERENCES

https://msrc.microsoft.com/update-guide/vulnerability/CVE-2026-58524

CVE-2026-58522

SUMMARY

Relative path traversal in Microsoft Edge for Android allows an unauthorized attacker to disclose information locally.

Published

Date2026-07-03

Updated

Date2026-07-03

RISK INFORMATION (Score: 6.8)

cvss3

Base Score: 6.8

Complexity: LOW

CVSS:3.1/AV:L/AC:L/PR:N/UI:N/S:U/C:H/I:L/A:N

Impact Score

4.2

Exploitability

2.5

REFERENCES

https://msrc.microsoft.com/update-guide/vulnerability/CVE-2026-58522

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…